Genetic Association Reveals Protection against Recurrence of


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
06 05 2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 16 7 2021
Statut: epublish

Résumé

Bezlotoxumab is a human monoclonal antibody against

Identifiants

pubmed: 32376702
pii: 5/3/e00232-20
doi: 10.1128/mSphere.00232-20
pmc: PMC7203456
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Broadly Neutralizing Antibodies 0
HLA-D Antigens 0
bezlotoxumab 4H5YMK1H2E

Banques de données

ClinicalTrials.gov
['NCT01241552', 'NCT01513239']

Types de publication

Clinical Trial, Phase III Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Shen et al.

Références

Cell. 2016 Nov 17;167(5):1398-1414.e24
pubmed: 27863251
PLoS Genet. 2014 May 15;10(5):e1004383
pubmed: 24830394
N Engl J Med. 2011 Feb 3;364(5):422-31
pubmed: 21288078
Clin Infect Dis. 2007 Aug 1;45(3):302-7
pubmed: 17599306
Nat Genet. 2012 Dec;44(12):1294-301
pubmed: 23104008
Science. 2014 Mar 7;343(6175):1246949
pubmed: 24604202
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Hum Hered. 2007;63(2):111-9
pubmed: 17283440
N Engl J Med. 2017 Jan 26;376(4):305-317
pubmed: 28121498
Hosp Pharm. 2015 Nov;50(11):1003-10
pubmed: 27621508
Clin Infect Dis. 2014 Jun;58(12):1723-30
pubmed: 24704722
Clin Infect Dis. 2012 Aug;55 Suppl 2:S65-70
pubmed: 22752867
Clin Infect Dis. 2008 Nov 1;47(9):1162-70
pubmed: 18808358
J Exp Med. 2003 Jun 2;197(11):1427-39
pubmed: 12782710
PLoS One. 2013 Jul 25;8(7):e69577
pubmed: 23936050
Clin Infect Dis. 2014 Jun;58(12):e148-51
pubmed: 24633688
Clin Infect Dis. 2010 Dec 15;51(12):1406-10
pubmed: 21058913
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
Clin Infect Dis. 2014 Aug 1;59(3):345-54
pubmed: 24799326
PLoS Genet. 2009 Jun;5(6):e1000529
pubmed: 19543373
Science. 2010 Dec 10;330(6010):1551-7
pubmed: 21051598
Clin Infect Dis. 2018 Mar 19;66(7):e1-e48
pubmed: 29462280
Clin Infect Dis. 2016 Mar 1;62(5):574-580
pubmed: 26582748
Nature. 2017 Oct 11;550(7675):204-213
pubmed: 29022597
Genet Epidemiol. 2009 Jan;33(1):79-86
pubmed: 18642345
Clin Pharmacol Drug Dev. 2020 Apr;9(3):330-340
pubmed: 31411386
J Hosp Infect. 1998 Feb;38(2):93-100
pubmed: 9522287
Clin Infect Dis. 2012 Aug;55 Suppl 2:S77-87
pubmed: 22752869
Clin Infect Dis. 2012 Aug;55(3):351-7
pubmed: 22523271
Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61
pubmed: 22752865
Scand J Gastroenterol. 1997 Sep;32(9):920-4
pubmed: 9299672
Clin Infect Dis. 2013 Jun;56(11):1589-600
pubmed: 23463640
Gut Microbes. 2010 Jan;1(1):58-64
pubmed: 20664812
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Lancet. 2001 Jan 20;357(9251):189-93
pubmed: 11213096
Clin Infect Dis. 2018 Aug 16;67(5):649-656
pubmed: 29538686
Immunogenetics. 2001 May-Jun;53(4):279-87
pubmed: 11491531
Pharmacogenomics J. 2014 Apr;14(2):192-200
pubmed: 23712092
Nat Rev Dis Primers. 2016 Apr 07;2:16020
pubmed: 27158839
Infect Immun. 2014 Feb;82(2):522-31
pubmed: 24478068
Clin Microbiol Infect. 2018 Jan;24(1):85.e1-85.e4
pubmed: 28782647

Auteurs

Judong Shen (J)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Devan V Mehrotra (DV)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Mary Beth Dorr (MB)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Zhen Zeng (Z)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Junhua Li (J)

BGI-Shenzhen, Shenzhen, China.
Shenzhen Key Laboratory of Unknown Pathogen Identification, Shenzhen, China.
School of Bioscience and Biotechnology, South China University of Technology, Guangzhou, China.

Xun Xu (X)

BGI-Shenzhen, Shenzhen, China.
Shenzhen Key Laboratory of Unknown Pathogen Identification, Shenzhen, China.

David Nickle (D)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Emily R Holzinger (ER)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Aparna Chhibber (A)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Mark H Wilcox (MH)

Leeds Teaching Hospital and University of Leeds, Leeds, United Kingdom.

Rebecca L Blanchard (RL)

Merck & Co., Inc., Kenilworth, New Jersey, USA.

Peter M Shaw (PM)

Merck & Co., Inc., Kenilworth, New Jersey, USA peter_shaw3@merck.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH